{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:03:59Z","timestamp":1783703039983,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In the past few decades, selective serotonin reuptake inhibitors (SSRIs) became widely used antidepressants worldwide. Therefore, the adverse reactions of patients after SSRI administration became a public and clinical concern. In this study, we conducted a pharmacovigilance study using the Adverse Event Reporting System (FAERS) database of the US Food and Drug Administration. Our main goal was to evaluate adverse events related to SSRIs, with a particular focus on abnormal weight gain and glucose\/lipid metabolism disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The adverse event data for representative SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) was extracted from the FAERS database from 2004Q1 to 2023Q4. The reporting odds ratio and proportional reporting ratio were employed to explore relevant adverse event reports (ADEs) signals. Univariate logistic regression analysis was utilized to explore factors associated with glucose\/lipid metabolism abnormality following SSRIs treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 143,744 ADE reports associated with SSRIs and revealed significant abnormal signals related to weight gain and glucose\/lipid metabolism in depressed patients. Variations were observed among different SSRIs medications. Specifically, citalopram was associated with abnormal weight gain (ROR: 4, 95% CI: 3.1-5.2) and hepatic steatosis (ROR: 2.8, 95% CI: 2.1-3.6); escitalopram was correlated with gestational diabetes (ROR: 9.1, 95% CI: 6.6-12.4) and cholestasis (ROR: 2.4, 95% CI: 1.75-3.38); fluoxetine was associated with obesity (ROR: 2.8, 95% CI: 2.08-3.78); fluvoxamine was linked to arteriospasm coronary (ROR: 13.87, 95% CI: 4.47-43.1); and sertraline was implicated in neonatal jaundice (ROR: 16.1, 95% CI: 12.6-20.6). Females and younger age are important risk factors for the development of associated adverse effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study screened for adverse effects associated with abnormal glucose\/lipid metabolism, such as abnormal body weight and fatty liver, in depressed patients taking selective serotonin reuptake inhibitors by utilizing FAERS database. This provides valuable insights for healthcare professionals in accepting and managing patients treated with SSRIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1517546","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T06:15:48Z","timestamp":1736489748000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Overweight and glucose\/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinming","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"CD002919","DOI":"10.1002\/14651858.CD002919.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults","volume":"4","author":"Banzi","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/add.12946","article-title":"Towards a comprehensive developmental model of pathological gambling","volume":"110","author":"Blanco","year":"2015","journal-title":"Addiction"},{"key":"B3","doi-asserted-by":"publisher","first-page":"CD006534","DOI":"10.1002\/14651858.CD006534.pub2","article-title":"Citalopram versus other anti-depressive agents for depression","volume":"7","author":"Cipriani","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.pnpbp.2017.03.016","article-title":"The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs","volume":"80","author":"Galecki","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajp.2015.10.006","article-title":"Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine","volume":"18","author":"Ghosh","year":"2015","journal-title":"Asian J. Psychiatr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s43440-019-00047-4","article-title":"Serotonin discovery and stepwise disclosure of 5-HT receptor complexity over four decades. Part II. Some contributions of Manfred Gothert","volume":"72","author":"Gothert","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pop.2022.10.010","article-title":"Geriatric depression","volume":"50","author":"Gundersen","year":"2023","journal-title":"Prim. Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1389450053174550","article-title":"Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity","volume":"6","author":"Halford","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-clinpsy-050817-084811","article-title":"Risk factors for depression: an autobiographical review","volume":"14","author":"Hammen","year":"2018","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1074\/jbc.AAC118.002476","article-title":"Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic \u03b2 cells","volume":"293","author":"Isaac","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41398-024-03185-3","article-title":"Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids","volume":"14","author":"Izumi","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41380-022-01824-z","article-title":"Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis","volume":"28","author":"Kishi","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/npp.2011.335","article-title":"Chronic fluoxetine selectively upregulates dopamine D\u2081-like receptors in the hippocampus","volume":"37","author":"Kobayashi","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pbb.2010.09.003","article-title":"Brain serotonin system in the coordination of food intake and body weight","volume":"97","author":"Lam","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11920-022-01372-x","article-title":"Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an updated review on risks to mother, fetus, and child","volume":"24","author":"Lebin","year":"2022","journal-title":"Curr. Psychiatry Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD001396","DOI":"10.1002\/14651858.CD001396.pub3","article-title":"Selective serotonin reuptake inhibitors for premenstrual syndrome","volume":"2013","author":"Marjoribanks","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/nyas.13467","article-title":"Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities","volume":"1411","author":"Mccuen-Wurst","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/13651501.2021.1872647","article-title":"The effects of selective serotonin reuptake inhibitors on male and female fertility: a brief literature review","volume":"26","author":"Milosavljevic","year":"2022","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.neubiorev.2013.01.008","article-title":"Depressive disorders and suicide: epidemiology, risk factors, and burden","volume":"37","author":"Miret","year":"2013","journal-title":"Neurosci. Biobehav Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coph.2008.12.006","article-title":"SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake","volume":"9","author":"Pinna","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.31887\/DCNS.2016.18.4\/ncutler","article-title":"Sex differences in the psychopharmacological treatment of depression","volume":"18","author":"Sramek","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(22)01012-1","article-title":"Depression in young people","volume":"400","author":"Thapar","year":"2022","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1176\/appi.ajp.2012.11121873","article-title":"Does fetal exposure to SSRIs or maternal depression impact infant growth?","volume":"170","author":"Wisner","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12888-023-05382-8","article-title":"Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis","volume":"23","author":"Yin","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40360-023-00713-7","article-title":"Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis","volume":"24","author":"Yu","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.7556\/jaoa.2019.016","article-title":"Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding","volume":"119","author":"Yuet","year":"2019","journal-title":"J. Am. Osteopath Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jad.2018.08.061","article-title":"A meta-analysis of selective serotonin reuptake inhibitors (SSRIs) use during prenatal depression and risk of low birth weight and small for gestational age","volume":"241","author":"Zhao","year":"2018","journal-title":"J. Affect Disord."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1517546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T06:15:53Z","timestamp":1736489753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1517546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":29,"alternative-id":["10.3389\/fphar.2024.1517546"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1517546","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"article-number":"1517546"}}